CLINICAL_TRIALS
trial_result
· 2019-01-07
Clinical Trial Update: Evaluation of Galcanezumab in the Prevention of Chronic Migraine [Phase 3]
Summary
Phase 3 trial evaluating galcanezumab for prevention of chronic migraine has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Chronic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2019-01-07